• Most study participants understand research goals (Reuters)

    Fri, 04 Jul 2008 07:29:02 PDT
    Reuters - People who take part in clinical trials often do so out of a desire to advance scientific knowledge and to help others, a new international study demonstrates.
  • Tongue-Driven Device Aids Handicapped (HealthDay)

    Thu, 03 Jul 2008 20:47:58 PDT
    HealthDay - THURSDAY, July 3 (HealthDay News) -- A tongue drive system that enables severely disabled people to operate powered wheelchairs and to perform other tasks has been developed by engineers at the Georgia Institute of Technology.
  • Freeze-Dried Formula May Block HIV Virus in Breast Milk (HealthDay)

    Thu, 03 Jul 2008 20:47:52 PDT
    HealthDay - THURSDAY, July 2 (HealthDay News) -- In developing countries where breast-feeding is a necessity, and HIV is rampant, the risk of disease transmission through breast milk might be reduced if infants were first fed a freeze-dried formula full of good bacteria that could capture and potentially destroy the deadly virus.
  • S.African addicts turn to AIDS medication to get high (AFP)

    Wed, 02 Jul 2008 10:07:25 PDT
    AFP - South African AIDS patients in Durban are under siege from drug addicts who rob them of their antiretroviral treatment to get high, the provincial health department said Wednesday.
  • Bush urges Congress to pass AIDS funds (Reuters)

    Wed, 02 Jul 2008 09:29:12 PDT
    Reuters - President George W. Bush urged Congress on Wednesday to approve funds to fight AIDS in Africa and other countries, and said the issue was high on his agenda for a Group of Eight summit in Japan next week.
  • Death Rates for HIV Patients Decrease Dramatically (HealthDay)

    Tue, 01 Jul 2008 20:46:56 PDT
    HealthDay - TUESDAY, July 1 (HealthDay News) -- Death rates for HIV-infected people lucky enough to get their hands on antiretroviral medications have decreased dramatically since the introduction of these drugs in 1996, new British research shows.
  • Anti-retroviral drug cocktails slash AIDS deaths: study (AFP)

    Tue, 01 Jul 2008 15:39:54 PDT
    AFP - Anti-retroviral drug therapy has slashed AIDS death rates in the first five years after infection to equal the normal death rates in developed countries, scientists said Tuesday.
  • People with HIV living longer, study shows (Reuters)

    Tue, 01 Jul 2008 13:25:44 PDT
    Reuters - People with HIV in the developed world are no more likely to die in the first five years following infection than men and women in the general population, British researchers said on Tuesday.
  • Political will helping India's AIDS battle: U.N. (Reuters)

    Mon, 30 Jun 2008 08:13:31 PDT
    Reuters - A strong political will was stimulating India's fight against AIDS, raising hopes of controlling its spread in the country with the world's third-largest caseload, the U.N.'s AIDS agency said on Monday.
  • NYC urges docs to do routine HIV testing on adults (AP)

    Thu, 26 Jun 2008 23:19:44 PDT
    AP - Health officials are trying to persuade doctors to offer HIV tests to nearly every patient in a New York City community hit harder than most by AIDS.

How supplied

ATRIPLA is available as tablets. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir DF (which is equivalent to 245 mg of tenofovir disoproxil). The tablets are pink, capsule-shaped, film-coated, debossed with "123" on one side and plain-faced on the other side. Each bottle contains 30 tablets (NDC 15584-0101-1) and silica gel desiccant, and is closed with a child-resistant closure.
Store at 25 °C (77 °F); excursions permitted to 15­30 °C (59­86 °F) [see USP Controlled Room Temperature].

  • Keep container tightly closed.
  • Dispense only in original container.
  • Do not use if seal over bottle opening is broken or missing.

July 2006
GS-21-937-001
EMTRIVA, TRUVADA, and VIREAD are trademarks of Gilead Sciences, Inc.
SUSTIVA is a trademark of Bristol-Myers Squibb Pharma Company. REYATAZ and VIDEX are trademarks of Bristol-Myers Squibb Company. PRAVACHOL® is a registered trademark of ER Squibb & Sons, LLC. Other brands listed are the
trademarks of their respective owners and are not trademarks of Gilead Sciences, Inc, Bristol-Myers Squibb Company, or Bristol-Myers Squibb & Gilead Sciences, LLC.
© 2006 Bristol-Myers Squibb & Gilead Sciences, LLC
© 2006 Bristol-Myers Squibb Company
© 2006 Gilead Sciences, Inc.